A Single Protein May Explain Why Lupus Attacks the Body - and How to Stop It
Only three drugs for lupus have cleared the FDA in the past six decades. For a disease that damages kidneys, ravages the brain, and affects millions of people worldwide, that number is quietly shocking. Carol Webb, a professor at the University of Oklahoma College of Medicine, has spent her career asking why - and a $1.7 million National Institutes of Health grant will let her keep digging.
The protein that should not be there
Webb's focus is a protein called ARID3a. In healthy people, the young B cells that the immune system produces do not contain it. In people with lupus, some of those same early-stage cells do. That distinction matters enormously.
B cells are the immune cells responsible for making antibodies. Before they mature, they pass through a quality-control checkpoint designed to screen out any cell that might target the body's own tissue. Webb's research suggests that ARID3a disrupts that checkpoint - allowing potentially harmful cells to graduate when they should be eliminated.
The numbers back this up. People with lupus carry higher counts of ARID3a-positive B cells than healthy individuals, and those with more of these cells tend to have more severe, more active disease. When Webb's team engineered mice to overproduce ARID3a in their B cells, the animals began generating antibodies that attacked their own tissue - the hallmark behavior of autoimmunity.
Three questions, one grant
The new NIH funding, awarded under grant number R01AI189437 from the National Institute of Allergy and Infectious Diseases, is structured around three concrete goals. First, the team wants to map the genes that ARID3a directly controls. Second, they want to understand the mechanism by which ARID3a helps young B cells bypass normal tolerance rules. Third, they want to test whether blocking ARID3a in mice actually reduces lupus symptoms.
"Lupus is a complicated disease in which the immune system turns against the body and can damage organs such as the kidneys and brain, making it especially challenging to study and treat," Webb said. "We believe these B cells may eventually help us detect disease earlier and guide the development of more effective, targeted therapies."
Why a targeted drug would be a genuine step forward
Most existing lupus treatments work by suppressing the immune system broadly. That approach brings down inflammation, but it also leaves patients vulnerable to infection and carries a long list of side effects. The appeal of targeting ARID3a specifically is that it might allow doctors to interrupt the self-attack without disabling the immune system's ability to fight real threats.
If the research goes well, ARID3a could serve two roles. As a biomarker, the density of these cells in a patient's blood might flag disease activity before symptoms worsen, giving clinicians an earlier warning. As a therapeutic target, blocking the protein's function could potentially cut off the production of the self-reactive antibodies that drive tissue damage.
Honest limits of what we know so far
The mouse models that support this hypothesis are suggestive, not conclusive. Lupus in humans is notoriously heterogeneous - no two patients have identical disease courses - and proteins that drive pathology in mice do not always translate to human biology. The work ahead involves both confirming the basic science and determining whether the magnitude of ARID3a's effect in people is large enough to be therapeutically meaningful.
Webb's path to this grant also involved a bridge award from the Presbyterian Health Foundation in Oklahoma City, which supported her work during a funding gap and helped position the team for the larger NIH award. For the roughly 1.5 million Americans living with lupus, having a specific molecular mechanism to interrogate is a precondition for real progress - and Webb now has the resources to pursue it.